Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Allogene Therapeutics, Inc. announced that the US FDA has cleared its Investigational New Drug application for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR T product.